Schuurhuis GJ - Search Results

1

AML/Normal Progenitor Balance Instead of Total Tumor Load (MRD) Accounts for Prognostic Impact of Flowcytometric Residual Disease in AML.

Hanekamp D, Tettero JM, Ossenkoppele GJ, Kelder A, Cloos J, Schuurhuis GJ. Hanekamp D, et al. Among authors: schuurhuis gj. Cancers (Basel). 2021 May 26;13(11):2597. doi: 10.3390/cancers13112597. Cancers (Basel). 2021. PMID: 34073205 Free PMC article.

2

Purging of peripheral blood stem cell transplants in AML: a predictive model based on minimal residual disease burden.

Feller N, Jansen-van der Weide MC, van der Pol MA, Westra GA, Ossenkoppele GJ, Schuurhuis GJ. Feller N, et al. Among authors: schuurhuis gj. Exp Hematol. 2005 Jan;33(1):120-30. doi: 10.1016/j.exphem.2004.10.007. Exp Hematol. 2005. PMID: 15661405 Free article. Clinical Trial.

3

High stem cell frequency in acute myeloid leukemia at diagnosis predicts high minimal residual disease and poor survival.

van Rhenen A, Feller N, Kelder A, Westra AH, Rombouts E, Zweegman S, van der Pol MA, Waisfisz Q, Ossenkoppele GJ, Schuurhuis GJ. van Rhenen A, et al. Among authors: schuurhuis gj. Clin Cancer Res. 2005 Sep 15;11(18):6520-7. doi: 10.1158/1078-0432.CCR-05-0468. Clin Cancer Res. 2005. PMID: 16166428 Free article.

4

Interleukin-2 receptor alpha-chain (CD25) expression on leukaemic blasts is predictive for outcome and level of residual disease in AML.

Terwijn M, Feller N, van Rhenen A, Kelder A, Westra G, Zweegman S, Ossenkoppele G, Schuurhuis GJ. Terwijn M, et al. Among authors: schuurhuis gj. Eur J Cancer. 2009 Jun;45(9):1692-9. doi: 10.1016/j.ejca.2009.02.021. Epub 2009 Mar 25. Eur J Cancer. 2009. PMID: 19321337

5

New approaches for the detection of minimal residual disease in acute myeloid leukemia.

van Rhenen A, Moshaver B, Ossenkoppele GJ, Schuurhuis GJ. van Rhenen A, et al. Among authors: schuurhuis gj. Curr Hematol Malig Rep. 2007 May;2(2):111-8. doi: 10.1007/s11899-007-0016-0. Curr Hematol Malig Rep. 2007. PMID: 20425359 Review.

6

MRD in AML: time for redefinition of CR?

Ossenkoppele G, Schuurhuis GJ. Ossenkoppele G, et al. Among authors: schuurhuis gj. Blood. 2013 Mar 21;121(12):2166-8. doi: 10.1182/blood-2013-01-480590. Blood. 2013. PMID: 23520326 Free article. No abstract available.

7

MRD in AML: it is time to change the definition of remission.

Ossenkoppele GJ, Schuurhuis GJ. Ossenkoppele GJ, et al. Among authors: schuurhuis gj. Best Pract Res Clin Haematol. 2014 Sep-Dec;27(3-4):265-71. doi: 10.1016/j.beha.2014.10.008. Epub 2014 Oct 15. Best Pract Res Clin Haematol. 2014. PMID: 25455276 Review.

8

MRD in AML: does it already guide therapy decision-making?

Ossenkoppele G, Schuurhuis GJ. Ossenkoppele G, et al. Among authors: schuurhuis gj. Hematology Am Soc Hematol Educ Program. 2016 Dec 2;2016(1):356-365. doi: 10.1182/asheducation-2016.1.356. Hematology Am Soc Hematol Educ Program. 2016. PMID: 27913502 Free PMC article. Review.

9

Leukemic stem cells: identification and clinical application.

Hanekamp D, Cloos J, Schuurhuis GJ. Hanekamp D, et al. Among authors: schuurhuis gj. Int J Hematol. 2017 May;105(5):549-557. doi: 10.1007/s12185-017-2221-5. Epub 2017 Mar 29. Int J Hematol. 2017. PMID: 28357569 Review.

10

Can we incorporate MRD assessment into clinical practice in AML?

Ossenkoppele G, Schuurhuis GJ, van de Loosdrecht A, Cloos J. Ossenkoppele G, et al. Among authors: schuurhuis gj. Best Pract Res Clin Haematol. 2019 Jun;32(2):186-191. doi: 10.1016/j.beha.2019.05.003. Epub 2019 May 10. Best Pract Res Clin Haematol. 2019. PMID: 31204000 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

175 results

Search Page